Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
11.5M
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
3.26M
-
Shares change
-
-88K
-
Total reported value, excl. options
-
$3.78M
-
Value change
-
-$96.8K
-
Put/Call ratio
-
0
-
Number of buys
-
8
-
Number of sells
-
-10
-
Price
-
$1.16
Significant Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) as of Q2 2025
44 filings reported holding TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.26M shares
of 11.5M outstanding shares and own 28.19% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (1.19M shares), Clearline Capital LP (635K shares), VANGUARD GROUP INC (379K shares), Tejara Capital Ltd (344K shares), ADAR1 Capital Management, LLC (209K shares), MORGAN STANLEY (131K shares), BlackRock, Inc. (116K shares), GEODE CAPITAL MANAGEMENT, LLC (109K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (34K shares), and STATE STREET CORP (30.1K shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.